Arrowstreet Capital
BCRX icon

Arrowstreet Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Arrowstreet Capital’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-66,244
Closed -$517K – 1843
2025
Q4 		$517K Sell
66,244
-5,159,742
-99% -$37.3M ﹤0.01% 1672
2025
Q3 		$39.7M Buy
5,225,986
+947,431
+22% +$7.89M 0.03% 529
2025
Q2 		$38.3M Buy
4,278,555
+4,084,403
+2,104% +$38M 0.03% 494
2025
Q1 		$1.46M Sell
194,152
-209,260
-52% -$1.69M ﹤0.01% 1388
2024
Q4 		$3.03M Sell
403,412
-27,818
-6% -$211K ﹤0.01% 1162
2024
Q3 		$3.28M Buy
+431,230
New +$3.28M ﹤0.01% 1096
2014
Q3 		– Sell
-36,011
Closed -$459K – 985
2014
Q2 		$459K Buy
+36,011
New +$350K ﹤0.01% 840

Other funds holding BCRX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return